Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01883999 · ClinicalTrials.gov registry record · NA
Evaluation of the GORE® EXCLUDER® Iliac Branch Endoprosthesis
A NA study of Aorto-iliac Aneurysms and Common Iliac Artery Aneurysms, sponsored by W.L.Gore & Associates.
- Completed
- Registry status
- NA
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT01883999: Completed NA study of Aorto-iliac Aneurysms and Common Iliac Artery Aneurysms, sponsored by W.L.Gore & Associates.
NCT01883999 is a NA study of Aorto-iliac Aneurysms and Common Iliac Artery Aneurysms that has completed, run by W.L.Gore & Associates. The registered enrollment target is 64 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01883999, a NA study of Aorto-iliac Aneurysms and Common Iliac Artery Aneurysms, has completed, sponsored by W.L.Gore & Associates.
- COMPLETED
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
The Iliac Branch Endoprosthesis (IBE) 12-04 study will be a prospective, nonrandomized, multicenter, single-arm evaluation designed to assess the safety and efficacy of the IBE Device in subjects with common iliac artery aneurysms (CIAA) or aorto-iliac aneurysms (AIA).
Primary Outcome
Freedom from composite of the following: Death, Stroke, Myocardial Infarction, Bowel Ischemia, Paraplegia, Respiratory Failure, Renal Failure, Conversion to open surgical repair.
Conditions Studied
Interventions
- DEVICE GORE® EXCLUDER® Iliac Branch Endoprosthesis
Study Locations (1)
New York
- Weill Cornell Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2013-10 |
| Est. Completion | 2021-06 |
| Phase | NA |
What the finished NCT01883999 record still lists
NCT01883999 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Aorto-iliac Aneurysms appearing as the primary indexed condition, and to 1 intervention - of which GORE® EXCLUDER® Iliac Branch Endoprosthesis is the first listed.
NCT01883999 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01883999 about?
NCT01883999 is a clinical study titled "Evaluation of the GORE® EXCLUDER® Iliac Branch Endoprosthesis". The Iliac Branch Endoprosthesis (IBE) 12-04 study will be a prospective, nonrandomized, multicenter, single-arm evaluation designed to assess the safety and efficacy of the IBE Device in subjects with common iliac artery aneurysms (CIAA) or aorto-iliac aneurysms (AIA).
What is the current status of trial NCT01883999?
This trial is currently completed. It is a NA study. The enrollment target is 64 participants. The study started on 2013-10. Estimated completion is 2021-06.
What conditions does trial NCT01883999 study?
This clinical trial studies the following conditions: Aorto-iliac Aneurysms, Common Iliac Artery Aneurysms.
What interventions are being tested in trial NCT01883999?
The interventions under investigation include: GORE® EXCLUDER® Iliac Branch Endoprosthesis (DEVICE).
Who is sponsoring clinical trial NCT01883999?
This trial is sponsored by W.L.Gore & Associates, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01883999 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aorto-iliac Aneurysms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01883999's enrollment target sits among peer trials
64 1147th of 2000 higher than 844 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia